tifcemalimab

Overview

Tifcemalimab (JS004) is an investigational anti-BTLA monoclonal antibody targeting BTLA (B and T lymphocyte attenuator), an inhibitory receptor implicated in T-cell exhaustion. It is evaluated in nasopharyngeal carcinoma (NPC).

Evidence in the corpus

• Tifcemalimab (JS004) anti-BTLA antibody under clinical investigation for R/M NPC; BTLA is implicated in T-cell exhaustion in NPC alongside CTLA-4, LAG-3, and TIM-3 as compensatory checkpoint mechanisms following PD-1/PD-L1 therapy PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.